Vivian E von Gruenigen1, Helen Q Huang2, David Cella3, MichaelA Zevon4, Jason A LaChance5, Joan L Walker6, Ritu Salani7, Susan C Modesitt8, Robert T Morris9, William H Bradley10, Matthew P Boente11, Lari Wenzel12. 1. Division of Gynecologic Oncology, Summa Health System, NEOMED, Akron, OH 44310, United States. Electronic address: vvongrue@neomed.edu. 2. NRG Oncology Statistics & Data Center, Roswell Park Cancer Institute, Buffalo, NY 14263, United States. Electronic address: hhuang@gogstats.org. 3. Department of Medical Social Sciences, Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL 60612, United States. Electronic address: d-cella@northwestern.edu. 4. Department of Health Behavior, Roswell Park Cancer Institute, Buffalo, NY 14263, United States. Electronic address: michael.zevon@roswellpark.org. 5. Program in Women's Oncology, Women and Infants Hospital, Providence, RI 02905, United States. Electronic address: lachaj1@mmc.org. 6. Stephenson Cancer Center, Department of Gynecologic Oncology, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, United States. Electronic address: joan-walker@ouhsc.edu. 7. Division of Gynecologic Oncology, The Ohio State University Medical Center, Columbus, OH 43210, United States. Electronic address: ritu.salani@osumc.edu. 8. Gynecologic Oncology Division, OB/GYN Department, University of Virginia, Charlottesville, VA 22908, United States. Electronic address: scm6h@virginia.edu. 9. Gynecologic Oncology Barbara Ann Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, MI, United States. Electronic address: rmorris@med.wayne.edu. 10. Department of OB/GYN; Medical College of Wisconsin, Milwaukee, WI 53226, United States. Electronic address: wbradley@mcw.edu. 11. U.S. Medical Affairs, Gyn-Oncology, Genentech, South San Francisco, CA 94080-4990, United States. Electronic address: boente.matthew@gene.com. 12. Population Science and Cancer Control/Chao Family Comprehensive Cancer Center at University of California at Irvine, Irvine, CA 92697, United States. Electronic address: lwenzel@uci.edu.
Abstract
OBJECTIVES: The goals of treating recurrent platinum-resistant ovarian cancer are palliative, aimed at reducing symptoms and improving progression free survival. A prospective trial was conducted to determine the prevalence and severity of symptoms, and associated care needs. METHODS: Eligible women included those with persistent or recurrent platinum-resistant ovarian cancer with an estimated life expectancy of at least 6 months. The Needs at the End-of-Life Screening Tool (NEST), FACIT-Fatigue (FACIT-F), NCCN-FACT Ovarian Symptom Index [NFOSI-18]; Disease Related Symptoms (DRS), Treatment Side Effects (TSE), and Function/Well Being (F/WB) were collected at study entry, 3 and 6 months. RESULTS: We enrolled 102 evaluable patients. Initiation of Do Not Resuscitate (DNR) discussions increased over time from 28% at study entry to 37% at 6 months. At study entry, the most common disease-related symptoms were fatigue (92%), worry (89%), and trouble sleeping (76%); 73% reported being "bothered by treatment side effects", which included nausea (41%) and hair loss (51%) neither of which changed over time. The most common NEST unmet needs were in the symptom dimension. The social dimension was associated with F/WB (p = 0.002) and FACIT-F (p = 0.006); symptoms were associated with DRS (p = 0.04), TSE (p = 0.03), and FACIT-F (p = 0.04); existential was not associated with any of the patient-reported symptoms; therapeutic was associated with F/WB (p = 0.02). CONCLUSIONS: In patients nearing the end of life, there are significant associations between disease and treatment related symptoms and unmet patient needs, which do not change substantially over time. Careful exploration of specific end-of-life care needs can improve patient-centered care and QOL.
OBJECTIVES: The goals of treating recurrent platinum-resistant ovarian cancer are palliative, aimed at reducing symptoms and improving progression free survival. A prospective trial was conducted to determine the prevalence and severity of symptoms, and associated care needs. METHODS: Eligible women included those with persistent or recurrent platinum-resistant ovarian cancer with an estimated life expectancy of at least 6 months. The Needs at the End-of-Life Screening Tool (NEST), FACIT-Fatigue (FACIT-F), NCCN-FACT Ovarian Symptom Index [NFOSI-18]; Disease Related Symptoms (DRS), Treatment Side Effects (TSE), and Function/Well Being (F/WB) were collected at study entry, 3 and 6 months. RESULTS: We enrolled 102 evaluable patients. Initiation of Do Not Resuscitate (DNR) discussions increased over time from 28% at study entry to 37% at 6 months. At study entry, the most common disease-related symptoms were fatigue (92%), worry (89%), and trouble sleeping (76%); 73% reported being "bothered by treatment side effects", which included nausea (41%) and hair loss (51%) neither of which changed over time. The most common NEST unmet needs were in the symptom dimension. The social dimension was associated with F/WB (p = 0.002) and FACIT-F (p = 0.006); symptoms were associated with DRS (p = 0.04), TSE (p = 0.03), and FACIT-F (p = 0.04); existential was not associated with any of the patient-reported symptoms; therapeutic was associated with F/WB (p = 0.02). CONCLUSIONS: In patients nearing the end of life, there are significant associations between disease and treatment related symptoms and unmet patient needs, which do not change substantially over time. Careful exploration of specific end-of-life care needs can improve patient-centered care and QOL.
Authors: K Basen-Engquist; D Bodurka-Bevers; M A Fitzgerald; K Webster; D Cella; S Hu; D M Gershenson Journal: J Clin Oncol Date: 2001-03-15 Impact factor: 44.544
Authors: Mounica Vallurupalli; Katharine Lauderdale; Michael J Balboni; Andrea C Phelps; Susan D Block; Andrea K Ng; Lisa A Kachnic; Tyler J Vanderweele; Tracy A Balboni Journal: J Support Oncol Date: 2011-11-16
Authors: Kristine A Donovan; Paul G Greene; John L Shuster; Edward E Partridge; Diane C Tucker Journal: Gynecol Oncol Date: 2002-08 Impact factor: 5.482
Authors: E A Eisenhauer; P Therasse; J Bogaerts; L H Schwartz; D Sargent; R Ford; J Dancey; S Arbuck; S Gwyther; M Mooney; L Rubinstein; L Shankar; L Dodd; R Kaplan; D Lacombe; J Verweij Journal: Eur J Cancer Date: 2009-01 Impact factor: 9.162
Authors: Rhea A Stein; Louise Sharpe; Melanie L Bell; Fran M Boyle; Stewart M Dunn; Stephen J Clarke Journal: J Clin Oncol Date: 2013-07-29 Impact factor: 44.544
Authors: Kristine A Donovan; Heidi S Donovan; David Cella; Martha E Gaines; Richard T Penson; Steven C Plaxe; Vivian E von Gruenigen; Deborah Watkins Bruner; Bryce B Reeve; Lari Wenzel Journal: J Natl Cancer Inst Date: 2014-07-08 Impact factor: 13.506
Authors: Anna Louise Beavis; Awa Sanneh; Rebecca L Stone; Margaret Vitale; Kimberly Levinson; Anne F Rositch; Amanda Nickles Fader; Kristin Topel; Ashley Abing; Stephanie L Wethington Journal: Am J Obstet Gynecol Date: 2020-05-17 Impact factor: 8.661
Authors: Lari Wenzel; Helen Q Huang; David Cella; Chelsea O McKinney; Michael A Zevon; Jason A LaChance; Joan L Walker; Ritu Salani; Susan C Modesitt; Robert T Morris; William H Bradley; Matthew P Boente; Vivian E von Gruenigen Journal: Gynecol Oncol Date: 2021-09-20 Impact factor: 5.482
Authors: Heidi S Donovan; Susan M Sereika; Lari B Wenzel; Robert P Edwards; Judith E Knapp; Susan H Hughes; Mary C Roberge; Teresa H Thomas; Sara Jo Klein; Michael B Spring; Susan Nolte; Lisa M Landrum; A Catherine Casey; David G Mutch; Robert L DeBernardo; Carolyn Y Muller; Stephanie A Sullivan; Sandra E Ward Journal: J Clin Oncol Date: 2022-02-07 Impact factor: 50.717